Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 1.40% to $18.78 Friday, on what proved to be an all-around great ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and ...

Corbus Pharmaceuticals Holdings ( (CRBP) ) has released its Q3 earnings. Here is a breakdown of the information Corbus Pharmaceuticals Holdings ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Corbus Pharmaceuticals Holdings ( NASDAQ:CRBP) stock is up 478% in the last year, providing strong gains for ...

Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701 ...

Procurement Outsourcing Services market is projected to grow from USD 7.5 Billion in 2024 to USD 15 Billion by 2032, at a CAGR of 8.3%.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, presents new pre-clinical data at ...

On Wednesday, B.Riley initiated coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and a price target of $85.00. The firm's coverage is based on the potential of... NORWOOD, MA ...